Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CHRO
Chromocell Therapeutics
$0.62
-6.1%
$0.78
$0.52
$6.00
$3.58MN/A62,976 shs50,998 shs
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$0.20
-4.3%
$0.19
$0.15
$1.33
$7.94M-0.91319,749 shs158,724 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.81
$0.67
$3.77
$3.37M1.1242,570 shsN/A
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
$2.53
+2.8%
$0.83
$0.26
$21.09
$431.74M0.324.98 million shs5.48 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CHRO
Chromocell Therapeutics
+2.76%-1.69%-7.24%-38.44%+65,869,900.00%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
+0.92%-7.57%+16.12%+2.10%-82.66%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%-1.35%-5.10%-78.42%
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
-3.53%-0.81%+567.75%+297.42%+245,999,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CHRO
Chromocell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.7326 of 5 stars
0.03.00.00.01.81.70.6
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.2343 of 5 stars
0.03.00.00.02.30.00.0
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
3.7097 of 5 stars
3.52.00.00.03.02.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CHRO
Chromocell Therapeutics
3.00
BuyN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
2.00
HoldN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/A
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
3.00
Buy$4.2066.01% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CHRO
Chromocell Therapeutics
N/AN/AN/AN/A($1.65) per shareN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$80K99.30N/AN/A$0.02 per share10.00
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$8.49M0.40N/AN/A$0.25 per share3.06
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
N/AN/AN/AN/A($1.10) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CHRO
Chromocell Therapeutics
-$7.38MN/A0.00N/AN/AN/A-580.00%N/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$21.27M-$0.47N/AN/AN/AN/A-5,710.19%-413.75%11/14/2024 (Estimated)
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/AN/A
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
-$70KN/A0.00N/AN/A-387.78%434.75%N/A

Latest COEP, CHRO, TVGN, and GENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/16/2024N/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$0.09-$0.08+$0.01-$0.08N/AN/A
8/13/2024Q2 2024
CHRO
Chromocell Therapeutics
N/A-$0.31-$0.31-$0.31N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CHRO
Chromocell Therapeutics
N/AN/AN/AN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CHRO
Chromocell Therapeutics
N/A
0.93
0.93
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/A
0.55
0.55
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
N/A
0.23
0.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CHRO
Chromocell Therapeutics
77.96%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
13.88%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
N/A

Insider Ownership

CompanyInsider Ownership
CHRO
Chromocell Therapeutics
16.40%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
21.49%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
6.46%
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
56.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CHRO
Chromocell Therapeutics
45.77 million4.82 millionN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
239.72 million31.18 millionNot Optionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Tevogen Bio Holdings Inc. stock logo
TVGN
Tevogen Bio
17170.65 million74.06 millionN/A

COEP, CHRO, TVGN, and GENE Headlines

Recent News About These Companies

Tevogen regains compliance with Nasdaq
Tevogen Bio plant nieuwe R&D- en productiefaciliteit
The TVGN Stock Mystery: Why Did TVGN Surge Today?
Tevogen AI joins Microsoft for Startups

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chromocell Therapeutics

NYSE:CHRO
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Coeptis Therapeutics logo

Coeptis Therapeutics

NASDAQ:COEP
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Genetic Technologies logo

Genetic Technologies

NASDAQ:GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Tevogen Bio logo

Tevogen Bio

NASDAQ:TVGN
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.